Clinical study of percutaneous liver tumor injection combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma
10.3760/cma.j.issn.1008-6706.2015.15.003
- VernacularTitle:经皮肝瘤内注射术联合经导管肝动脉化疗栓塞术治疗中晚期肝癌的临床研究
- Author:
Wenyuan CHENG
;
Zhenhua DAI
;
Lixia LOU
;
Yunfeng FENG
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Percutaneous liver tumor injection;
Transcatheter arterial chemoembolization
- From:
Chinese Journal of Primary Medicine and Pharmacy
2015;(15):2247-2249,2250
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects of percutaneous liver tumor injection combined with the clinical efficacy of transcatheter hepatic artery chemoembolization in the treatment of advanced liver cancer,and to provide ref-erence for clinical treatment.Methods 22 patients using percutaneous liver tumor injection combined with transcath-eter arterial chemoembolization for treatment were selected,with which 1 month follow-up after discharge.Situation of patients with percutaneous liver tumor injection and transcatheter hepatic artery chemoembolization was analyzed,and the changes of the patients in the following -up of survival time,tumor volume and clinical symptoms were also ana-lyzed.Results Among the patients of postoperative recheck after 6 weeks,6 cases were complete remission,there were partial remission in 8 cases,6 cases of stable,2 cases of progress.Follow up to 2013 December,the patients'sur-vival time was 17-82 months,the average survival time was (55.71 ±13.47)months.After treatment,4 cases of patients'tumor diameter reduced 1 -3cm,18 cases of tumor diameter reduced 3 -5cm,19 cases of liver area pain symptoms for more than half a year of remission,3 cases of liver area pain relief time less than half a year.During the follow -up period,12 patients died of multiple organ failure.Conclusion The development of percutaneous liver tumor injection combined with transcatheter hepatic arterial chemoembolization therapy can delay the development of the disease in patients with advanced HCC,and prolong the survival time.
